Janssen Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

Adam Savitz

Srihari Gopal

Wayne C Drevets

Vanina Popova

Iva Kezic

Mark Schmidt

Rama Melkote

Darrel Pemberton

Chakradhar Lagishetty

Philippe Fernandes

Vaibhav Narayan

Geert Van Der Avoort

Nicolaas Martha Felix Goyvaerts

Laura Martinez Marcos

Tom Huybrechts

Tatiana Marcozzi

Mahesh N Samtani

Dai Wang

Susan Baker

Matthieu Ravelingien

Katarina Jokicevic

The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Compositions and methods for the treatment of depression

The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.

Compositions comprising aticaprant

The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Forms of aticaprant

The invention provides methods of identifying schizophrenia patients at risk for relapse. The invention also provides methods of early detection of schizophrenic relapse. The disclosed methods use monitoring of a subset of symptoms and/or one or more biomarkers. The symptom severity can be assessed using the Positive and Negative Syndrome Scale (PANSS) parameters. The methods of the invention can be used to provide early intervention to decrease or prevent relapse in schizophrenia patients.

Methods of identifying schizophrenia patients at risk for relapse

Growing community of inventors

Greenwich, CT, United States of America

Adam Savitz